RxDoctor Payments Data

Angeles Lai-Zayas, MD

Internal Medicine · Pasadena, TXNPI 1730136862

Payments from drug & device makers

$738in general payments, 2019–2025

Across 36 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$176
  • Novo Nordisk$152
  • Bayer$82
  • Amgen$62
  • AbbVie$45
  • AstraZeneca$41
  • plus $182 from 8 others

What the payments were for

  • Food & beverage$738100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$738 in reported general payments places this provider in the 65th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$87,121
Medicare patients
195
Services billed
1,238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide113$224,550
FarxigaDapagliflozin Propanediol137$161,142
OzempicSemaglutide60$109,057
JardianceEmpagliflozin51$75,009
EliquisApixaban54$65,106
MounjaroTirzepatide30$53,156
JanuviaSitagliptin Phosphate35$49,541
Tresiba Flextouch U-100Insulin Degludec43$41,209
LinzessLinaclotide33$36,260
MyrbetriqMirabegron18$18,327
Xigduo XrDapaglifloz Propaned/Metformin13$18,228
XareltoRivaroxaban13$17,568
TradjentaLinagliptin16$16,763
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp11$8,739
Atorvastatin Calcium799$8,633

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$30$277,707143 claims
AstraZenecaFarxiga, Symbicort$41$165,998149 claims
Novo NordiskOzempic$152$109,05760 claims
Boehringer IngelheimJardiance, Tradjenta$17$91,77167 claims
PfizerEliquis, Premarin, Paxlovid$37$74,13091 claims
AbbVieLinzess$45$36,26033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Pasadena

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →